 |
88 Diseases |  |
13 Trials |
|
13 Trials |  |
791 News |  |
| «123456789101112 |
- Epogen (epoetin alfa) / Amgen, Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Trial completion: Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer (clinicaltrials.gov) - Jun 17, 2012
P3, N=14, Completed, Sponsor: Jonsson Comprehensive Cancer Center
Active, not recruiting --> Completed
- Epogen (epoetin alfa) / Amgen
Trial completion: REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction (clinicaltrials.gov) - May 17, 2012
P2, N=250, Completed, Sponsor: National Institute on Aging (NIA)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Evrenzo (roxadustat) / FibroGen
New P2 trial: Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China (clinicaltrials.gov) - May 9, 2012
P2, N=96, Completed, Sponsor: FibroGen
- MK-2578 (darbepoetin alfa biosimilar) / Merck (MSD)
Enrollment change: A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12) (clinicaltrials.gov) - Feb 27, 2012
P2, N=39, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=158 --> 39
- | Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
Enrollment change, Metastases: A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis. (clinicaltrials.gov) - Dec 14, 2011
P3, N=111, Terminated, Sponsor: Hoffmann-La Roche
N=158 --> 39 N=2121 --> 111
- | Epogen (epoetin alfa) / Amgen
New P2 trial: FRIEMAX: Efficacy Study of Epoetin Alfa in Friedreich Ataxia (clinicaltrials.gov) - Dec 14, 2011
P2, N=56, Active, not recruiting, Sponsor: Federico II University
- Epogen (epoetin alfa) / Amgen
Enrollment closed: Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF) (clinicaltrials.gov) - Nov 27, 2011
P2, N=80, Active, not recruiting, Sponsor: Columbia University
N=2121 --> 111 Recruiting --> Active, not recruiting
- |||||||||| Epogen (epoetin alfa) / Amgen, Omontys (peginesatide) / Affymax
New P3 trial: DIAMOND: Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - Nov 22, 2011
P3, N=184, Completed, Sponsor: Affymax
- ||||||| Victrelis (boceprevir) / Roche, Merck (MSD)
Trial completion: Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2) (clinicaltrials.gov) - Nov 21, 2011
P3, N=687, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Epogen (epoetin alfa) / Amgen
New P3 trial: A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin (clinicaltrials.gov) - Nov 15, 2011
P3, N=320, Completed, Sponsor: Hospira, Inc.
- |||||||||| Epogen (epoetin alfa) / Amgen
New P3 trial: AiME - 01: A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin (clinicaltrials.gov) - Nov 15, 2011
P3, N=612, Completed, Sponsor: Hospira, Inc.
- Epogen (epoetin alfa) / Amgen
Enrollment change: Prevalence and Treatment of Anemia in Rehabilitation Patients (clinicaltrials.gov) - Nov 8, 2011
P4, N=22, Terminated, Sponsor: University of Medicine and Dentistry of New Jersey
Active, not recruiting --> Completed N=72 --> 22
- | Epogen (epoetin alfa) / Amgen
Enrollment change, HEOR: CEDOSE: The Clinical Evaluation of the Dose of Erythropoietins Trial (clinicaltrials.gov) - Nov 6, 2011
P3, N=900, Recruiting, Sponsor: Consorzio Mario Negri Sud
N=72 --> 22 N=2204 --> 900
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: DREXNECK: Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Nov 6, 2011
P2, N=25, Recruiting, Sponsor: Drexel University
- Epogen (epoetin alfa) / Amgen
Trial withdrawal, Metastases: Using Iron With Procrit in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia (clinicaltrials.gov) - Sep 19, 2011
P2, N=0, Withdrawn, Sponsor: James Graham Brown Cancer Center
N=2204 --> 900 Completed --> Withdrawn
- Epogen (epoetin alfa) / Amgen
Trial withdrawal: REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx (clinicaltrials.gov) - Sep 1, 2011
P2b, N=30, Withdrawn, Sponsor: Stem Cell Therapeutics Corp.
Completed --> Withdrawn Terminated --> Withdrawn
- Epogen (epoetin alfa) / Amgen
Trial withdrawal: Epoetin Alfa for HIV-Associated Neuropathy Trial (clinicaltrials.gov) - Aug 7, 2011
P2, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Terminated --> Withdrawn Terminated --> Withdrawn